Hehnke, Uwe
Boehringer Ingelheim (Germany)
4 papers on CoChat
Most cited papers
- Verified
Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME
Verma, S., Mazer, C. D., Al-Omran, M., Inzucchi, S. E., Fitchett, D., Hehnke, U., George, J. T., & Zinman, B. (2018) · Circulation
Diabetes Treatment and ManagementPeripheral Artery Disease Management
Cited by 166
- Verified
Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control
Inzucchi, S. E., Kosiborod, M., Fitchett, D., Wanner, C., Hehnke, U., Kaspers, S., George, J. T., & Zinman, B. (2018) · Circulation
Diabetes Treatment and ManagementHeart Failure Treatment and Management
Cited by 162
- Verified
Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes
Cooper, M. E., Perkovic, V., McGill, J. B., Groop, P.-H., Wanner, C., Rosenstock, J., Hehnke, U., Woerle, H.-J., & von Eynatten, M. (2015) · American Journal of Kidney Diseases
Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes
Cited by 110
- Verified
Efficacy and safety of linagliptin in 2681 Asian patients stratified by age, obesity, and renal function: A pooled analysis of randomized clinical trials
Ning, G., Bandgar, T., Hehnke, U., Lee, J., & Chan, J. C. N. (2017) · Advances in Therapy
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 13
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free